Barclays PLC Allogene Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 342,973 shares of ALLO stock, worth $641,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares

342,973

Previous 342,973 -0.0%

Holding current value

$641,359

Previous $959,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.08 - $3.5 $359,309 - $604,607	172,745 Added 101.48%	342,973 $959,000
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $30,062 - $59,046	13,481 Added 8.6%	170,228 $396,000
Q1 2024 May 15, 2024	SELL	$2.92 - $5.63 $82,227 - $158,540	-28,160 Reduced 15.23%	156,747 $700,000
Q4 2023 Feb 15, 2024	SELL	$2.28 - $3.5 $1.37 Million - $2.11 Million	-601,886 Reduced 76.5%	184,907 $594,000
Q3 2023 Nov 07, 2023	BUY	$3.17 - $5.96 $372,779 - $700,872	117,596 Added 17.57%	786,793 $2.5 Million
Q2 2023 Aug 03, 2023	BUY	$4.53 - $6.74 $763,513 - $1.14 Million	168,546 Added 33.67%	669,197 $3.33 Million
Q1 2023 May 04, 2023	BUY	$4.92 - $8.21 $381,782 - $637,079	77,598 Added 18.34%	500,651 $2.47 Million
Q4 2022 Feb 13, 2023	BUY	$5.62 - $11.11 $591,712 - $1.17 Million	105,287 Added 33.13%	423,053 $2.66 Million
Q3 2022 Nov 03, 2022	BUY	$10.32 - $17.28 $2.96 Million - $4.96 Million	287,087 Added 935.78%	317,766 $3.43 Million
Q2 2022 Aug 12, 2022	SELL	$6.78 - $12.28 $499,631 - $904,937	-73,692 Reduced 70.61%	30,679 $350,000
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $30,898 - $61,756	4,039 Added 4.03%	104,371 $951,000
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $742,921 - $1.39 Million	56,582 Added 129.33%	100,332 $1.5 Million
Q3 2021 Nov 09, 2021	SELL	$21.01 - $27.64 $1.1 Million - $1.44 Million	-52,184 Reduced 54.4%	43,750 $1.12 Million
Q2 2021 Aug 13, 2021	SELL	$23.49 - $35.8 $788,888 - $1.2 Million	-33,584 Reduced 25.93%	95,934 $2.5 Million
Q1 2021 May 13, 2021	BUY	$25.79 - $39.02 $1.76 Million - $2.66 Million	68,113 Added 110.92%	129,518 $4.57 Million
Q4 2020 Feb 11, 2021	SELL	$25.24 - $43.45 $451,770 - $777,711	-17,899 Reduced 22.57%	61,405 $1.55 Million
Q3 2020 Nov 12, 2020	SELL	$32.38 - $44.96 $301,360 - $418,442	-9,307 Reduced 10.5%	79,304 $2.99 Million
Q2 2020 Aug 12, 2020	BUY	$18.39 - $54.04 $489,707 - $1.44 Million	26,629 Added 42.96%	88,611 $3.8 Million
Q1 2020 May 13, 2020	BUY	$18.22 - $28.25 $253,185 - $392,562	13,896 Added 28.9%	61,982 $1.2 Million
Q4 2019 Feb 10, 2020	BUY	$24.82 - $31.4 $402,009 - $508,585	16,197 Added 50.79%	48,086 $1.25 Million
Q3 2019 Nov 14, 2019	BUY	$26.11 - $32.99 $179,715 - $227,070	6,883 Added 27.53%	31,889 $870,000
Q2 2019 Aug 14, 2019	SELL	$25.56 - $31.09 $127,927 - $155,605	-5,005 Reduced 16.68%	25,006 $671,000
Q1 2019 May 15, 2019	BUY	$24.82 - $32.54 $720,450 - $944,538	29,027 Added 2949.9%	30,011 $868,000
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $22,140 - $32,767	984 New	984 $27,000

Others Institutions Holding ALLO

# of Institutions

163

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $269M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account